Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. (May 2022)
- Record Type:
- Journal Article
- Title:
- Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. (May 2022)
- Main Title:
- Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
- Authors:
- Blach, Sarah
Terrault, Norah A
Tacke, Frank
Gamkrelidze, Ivane
Craxi, Antonio
Tanaka, Junko
Waked, Imam
Dore, Gregory J
Abbas, Zaigham
Abdallah, Ayat R
Abdulla, Maheeba
Aghemo, Alessio
Aho, Inka
Akarca, Ulus S
Alalwan, Abduljaleel M
Alanko Blomé, Marianne
Al-Busafi, Said A
Aleman, Soo
Alghamdi, Abdullah S
Al-Hamoudi, Waleed K
Aljumah, Abdulrahman A
Al-Naamani, Khalid
Al Serkal, Yousif M
Altraif, Ibrahim H
Anand, Anil C
Anderson, Motswedi
Andersson, Monique I
Athanasakis, Kostas
Baatarkhuu, Oidov
Bakieva, Shokhista R
Ben-Ari, Ziv
Bessone, Fernando
Biondi, Mia J
Bizri, Abdul Rahman N
Brandão-Mello, Carlos E
Brigida, Krestina
Brown, Kimberly A
Brown, Jr, Robert S
Bruggmann, Philip
Brunetto, Maurizia R
Busschots, Dana
Buti, Maria
Butsashvili, Maia
Cabezas, Joaquin
Chae, Chungman
Chaloska Ivanova, Viktorija
Chan, Henry Lik Yuen
Cheinquer, Hugo
Cheng, Kent Jason
Cheon, Myeong-Eun
Chien, Cheng-Hung
Chien, Rong-Nan
Choudhuri, Gourdas
Christensen, Peer Brehm
Chuang, Wan-Long
Chulanov, Vladimir
Cisneros, Laura E
Coco, Barbara
Contreras, Fernando A
Cornberg, Markus
Cramp, Matthew E
Crespo, Javier
Cui, Fuqiang
Cunningham, Chris W
Dagher Abou, Lucy
Dalgard, Olav
Dao, Doan Y
De Ledinghen, Victor
Derbala, Moutaz F
Deuba, Keshab
Dhindsa, Karan
Djauzi, Samsuridjal
Drazilova, Sylvia
Duberg, Ann-Sofi
Elbadri, Mohammed
El-Sayed, Manal H
Esmat, Gamal
Estes, Chris
Ezzat, Sameera
Färkkilä, Martti A
Ferradini, Laurent
Ferraz, Maria Lucia G
Ferreira, Paulo R A
Filipec Kanizaj, Tajana
Flisiak, Robert
Frankova, Sona
Fung, James
Gamkrelidze, Amiran
Gane, Edward
Garcia, Virginia
García-Samaniego, Javier
Gemilyan, Manik
Genov, Jordan
Gheorghe, Liliana S
Gholam, Pierre M
Goldis, Adrian
Gottfredsson, Magnus
Gray, Richard T
Grebely, Jason
Gschwantler, Michael
Hajarizadeh, Behzad
Hamid, Saeed S
Hamoudi, Waseem
Hatzakis, Angelos
Hellard, Margaret E
Himatt, Sayed
Hofer, Harald
Hrstic, Irena
Hunyady, Bela
Husa, Petr
Husic-Selimovic, Azra
Jafri, Wasim S M
Janicko, Martin
Janjua, Naveed
Jarcuska, Peter
Jaroszewicz, Jerzy
Jerkeman, Anna
Jeruma, Agita
Jia, Jidong
Jonasson, Jon G
Kåberg, Martin
Kaita, Kelly D E
Kaliaskarova, Kulpash S
Kao, Jia-Horng
Kasymov, Omor T
Kelly-Hanku, Angela
Khamis, Faryal
Khamis, Jawad
Khan, Aamir G
Khandu, Lekey
Khoudri, Ibtissam
Kielland, Knut B
Kim, Do Young
Kodjoh, Nicolas
Kondili, Loreta A
Krajden, Mel
Krarup, Henrik Bygum
Kristian, Pavol
Kwon, Jisoo A
Lagging, Martin
Laleman, Wim
Lao, Wai Cheung
Lavanchy, Daniel
Lázaro, Pablo
Lazarus, Jeffrey V
Lee, Alice U
Lee, Mei-Hsuan
Li, Michael K K
Liakina, Valentina
Lim, Young-Suk
Löve, Arthur
Lukšić, Boris
Machekera, Shepherd Mufudzi
Malu, Abraham O
Marinho, Rui T
Maticic, Mojca
Mekonnen, Hailemichael D
Mendes-Correa, Maria Cássia
Mendez-Sanchez, Nahum
Merat, Shahin
Meshesha, Berhane Redae
Midgard, Håvard
Mills, Mike
Mohamed, Rosmawati
Mooneyhan, Ellen
Moreno, Christophe
Muljono, David H
Müllhaupt, Beat
Musabaev, Erkin
Muyldermans, Gaëtan
Nartey, Yvonne Ayerki
Naveira, Marcelo C M
Negro, Francesco
Nersesov, Alexander V
Njouom, Richard
Ntagirabiri, Rénovat
Nurmatov, Zuridin S
Obekpa, Solomon A
Oguche, Stephen
Olafsson, Sigurdur
Ong, Janus P
Opare-Sem, Ohene K
Orrego, Mauricio
Øvrehus, Anne L
Pan, Calvin Q
Papatheodoridis, George V
Peck-Radosavljevic, Markus
Pessoa, Mário G
Phillips, Richard O
Pimenov, Nikolay
Plaseska-Karanfilska, Dijana
Prabdial-Sing, Nishi N
Puri, Pankaj
Qureshi, Huma
Rahman, Aninda
Ramji, Alnoor
Razavi-Shearer, Devin M
Razavi-Shearer, Kathryn
Ridruejo, Ezequiel
Ríos-Hincapié, Cielo Y
Rizvi, S M Shahriar
Robaeys, Geert K M M
Roberts, Lewis R
Roberts, Stuart K
Ryder, Stephen D
Sadirova, Shakhlo
Saeed, Umar
Safadi, Rifaat
Sagalova, Olga
Said, Sanaa S
Salupere, Riina
Sanai, Faisal M
Sanchez-Avila, Juan F
Saraswat, Vivek A
Sarrazin, Christoph
Sarybayeva, Gulya
Seguin-Devaux, Carole
Sharara, Ala I
Sheikh, Mahdi
Shewaye, Abate B
Sievert, William
Simojoki, Kaarlo
Simonova, Marieta Y
Sonderup, Mark W
Spearman, C Wendy
Sperl, Jan
Stauber, Rudolf E
Stedman, Catherine A M
Su, Tung-Hung
Suleiman, Anita
Sypsa, Vana
Tamayo Antabak, Natalia
Tan, Soek-Siam
Tergast, Tammo L
Thurairajah, Prem H
Tolmane, Ieva
Tomasiewicz, Krzysztof
Tsereteli, Maia
Uzochukwu, Benjamin S C
Van De Vijver, David A M C
Van Santen, Daniela K
Van Vlierberghe, Hans
Van Welzen, Berend
Vanwolleghem, Thomas
Vélez-Möller, Patricia
Villamil, Federico
Vince, Adriana
Waheed, Yasir
Weis, Nina
Wong, Vincent W-S
Yaghi, Cesar G
Yesmembetov, Kakharman
Yosry, Ayman
Yuen, Man-Fung
Yunihastuti, Evy
Zeuzem, Stefan
Zuckerman, Eli
Razavi, Homie A
… (more) - Abstract:
- Summary: Background: Since the release of the first global hepatitis elimination targets in 2016, and until the COVID-19 pandemic started in early 2020, many countries and territories were making progress toward hepatitis C virus (HCV) elimination. This study aims to evaluate HCV burden in 2020, and forecast HCV burden by 2030 given current trends. Methods: This analysis includes a literature review, Delphi process, and mathematical modelling to estimate HCV prevalence (viraemic infection, defined as HCV RNA-positive cases) and the cascade of care among people of all ages (age ≥0 years from birth) for the period between Jan 1, 2015, and Dec 31, 2030. Epidemiological data were collected from published sources and grey literature (including government reports and personal communications) and were validated among country and territory experts. A Markov model was used to forecast disease burden and cascade of care from 1950 to 2050 for countries and territories with data. Model outcomes were extracted from 2015 to 2030 to calculate population-weighted regional averages, which were used for countries or territories without data. Regional and global estimates of HCV prevalence, cascade of care, and disease burden were calculated based on 235 countries and territories. Findings: Models were built for 110 countries or territories: 83 were approved by local experts and 27 were based on published data alone. Using data from these models, plus population-weighted regional averages forSummary: Background: Since the release of the first global hepatitis elimination targets in 2016, and until the COVID-19 pandemic started in early 2020, many countries and territories were making progress toward hepatitis C virus (HCV) elimination. This study aims to evaluate HCV burden in 2020, and forecast HCV burden by 2030 given current trends. Methods: This analysis includes a literature review, Delphi process, and mathematical modelling to estimate HCV prevalence (viraemic infection, defined as HCV RNA-positive cases) and the cascade of care among people of all ages (age ≥0 years from birth) for the period between Jan 1, 2015, and Dec 31, 2030. Epidemiological data were collected from published sources and grey literature (including government reports and personal communications) and were validated among country and territory experts. A Markov model was used to forecast disease burden and cascade of care from 1950 to 2050 for countries and territories with data. Model outcomes were extracted from 2015 to 2030 to calculate population-weighted regional averages, which were used for countries or territories without data. Regional and global estimates of HCV prevalence, cascade of care, and disease burden were calculated based on 235 countries and territories. Findings: Models were built for 110 countries or territories: 83 were approved by local experts and 27 were based on published data alone. Using data from these models, plus population-weighted regional averages for countries and territories without models (n=125), we estimated a global prevalence of viraemic HCV infection of 0·7% (95% UI 0·7–0·9), corresponding to 56·8 million (95% UI 55·2–67·8) infections, on Jan 1, 2020. This number represents a decrease of 6·8 million viraemic infections from a 2015 (beginning of year) prevalence estimate of 63·6 million (61·8–75·8) infections (0·9% [0·8–1·0] prevalence). By the end of 2020, an estimated 12·9 million (12·5–15·4) people were living with a diagnosed viraemic infection. In 2020, an estimated 641 000 (623 000–765 000) patients initiated treatment. Interpretation: At the beginning of 2020, there were an estimated 56·8 million viraemic HCV infections globally. Although this number represents a decrease from 2015, our forecasts suggest we are not currently on track to achieve global elimination targets by 2030. As countries recover from COVID-19, these findings can help refocus efforts aimed at HCV elimination. Funding: John C Martin Foundation, Gilead Sciences, AbbVie, ZeShan Foundation, and The Hepatitis Fund. … (more)
- Is Part Of:
- Lancet gastroenterology and hepatology. Volume 7:Number 5(2022)
- Journal:
- Lancet gastroenterology and hepatology
- Issue:
- Volume 7:Number 5(2022)
- Issue Display:
- Volume 7, Issue 5 (2022)
- Year:
- 2022
- Volume:
- 7
- Issue:
- 5
- Issue Sort Value:
- 2022-0007-0005-0000
- Page Start:
- 396
- Page End:
- 415
- Publication Date:
- 2022-05
- Journal URLs:
- http://www.sciencedirect.com/ ↗
- DOI:
- 10.1016/S2468-1253(21)00472-6 ↗
- Languages:
- English
- ISSNs:
- 2468-1253
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5146.081000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21268.xml